Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 18/20 | 0.80 |
| ▸ | EGFR | P00533 | 2/20 | 0.43 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.41 |
| ▸ | SRC | P12931 | 1/20 | 0.41 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.41 |
| ▸ | LCK | P06239 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL174843 | 1.00 | BTK (0.80) | BTKEGFRFGFR4SRCTNK2 | |
| SCHEMBL166896 | 0.89 | BTK (1.00) | BTKEGFRTNK2 | |
| SCHEMBL19993798 | 0.89 | BTK (1.00) | BTKEGFRTNK2 | |
| SCHEMBL16333090 | 0.88 | BTK (0.69) | BTKTNK2 | |
| SCHEMBL21648610 | 0.82 | BTK (0.78) | BTKTNK2 | |
| SCHEMBL16788366 | 0.82 | BTK (0.86) | BTKEGFR | |
| SCHEMBL19986670 | 0.82 | BTK (0.86) | BTKEGFR | |
| SCHEMBL124181 | 0.81 | BTK (0.82) | BTKEGFRTNK2 | |
| SCHEMBL122280 | 0.81 | BTK (1.00) | BTKEGFRTNK2 | |
| SCHEMBL124553 | 0.80 | BTK (0.69) | BTKTNK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2424368-B1 | PYRROLOTRIAZINE COMPOUNDS | LOCUS PHARMACEUTICALS INC (US) | 2014-12-31 | — | — | EP | claimed |
| US-8765754-B2 | Pyrrolotriazine compounds | LOCUS PHARMACEUTICALS, INC. (US) | 2014-07-01 | — | — | US | claimed |
| US-20120232054-A1 | PYRROLOTRIAZINE COMPOUNDS | LOCUS PHARMACEUTICALS, INC. (US) | 2012-09-13 | — | — | US | claimed |
| EP-2424368-A1 | PYRROLOTRIAZINE COMPOUNDS | Locus Pharmaceuticals, Inc. (US) | 2012-03-07 | — | — | EP | claimed |
| WO-2010126960-A1 | PYRROLOTRIAZINE COMPOUNDS | LOCUS PHARMACEUTICALS, INC. (US) | 2010-11-04 | — | — | WO | claimed |
| US-20160074409-A1 | Treatment of Skeletal-Related Disorders | ROTHBAUM WAYNE (US) | 2016-03-17 | — | — | US | disclosed |
| EP-2424368-B1 | PYRROLOTRIAZINE COMPOUNDS | LOCUS PHARMACEUTICALS INC (US) | 2014-12-31 | — | — | EP | disclosed |
| US-20140357636-A1 | Treatment of Skeletal-Related Disorders | ROTHBAUM WAYNE (US) | 2014-12-04 | — | — | US | disclosed |
| US-8765754-B2 | Pyrrolotriazine compounds | LOCUS PHARMACEUTICALS, INC. (US) | 2014-07-01 | — | — | US | disclosed |
| US-20120232054-A1 | PYRROLOTRIAZINE COMPOUNDS | LOCUS PHARMACEUTICALS, INC. (US) | 2012-09-13 | — | — | US | disclosed |
| EP-2424368-A1 | PYRROLOTRIAZINE COMPOUNDS | Locus Pharmaceuticals, Inc. (US) | 2012-03-07 | — | — | EP | disclosed |
| WO-2010126960-A1 | PYRROLOTRIAZINE COMPOUNDS | LOCUS PHARMACEUTICALS, INC. (US) | 2010-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160074409-A1 | Treatment of Skeletal-Related Disorders | SOST, COL2A1, CYP27B1 | BTK 4374/4885EGFR 4530/4885FGFR4 218/4885 |
| US-20140357636-A1 | Treatment of Skeletal-Related Disorders | SOST, COL2A1, CYP27B1 | BTK 4374/4885EGFR 4530/4885FGFR4 218/4885 |
| US-20120232054-A1 | PYRROLOTRIAZINE COMPOUNDS | BTK, SYK, ZAP70 | BTK 1/4885EGFR 3296/4885FGFR4 2684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.